https://doi.org/10.55788/337f1df0
“Achieving (sustained) MRD negativity at 10-6 translates into very long survival outcomes for patients with MM and standard risk features,” outlined Prof. Pieter Sonneveld (Erasmus University Medical Center, the Netherlands) [1]. The earlier, primary analysis of the PERSEUS study (NCT03710603; n=709) demonstrated that induction and consolidation with D-VRd followed by maintenance with daratumumab-lenalidomide (D-R) maintenance was superior to induction and consolidation with VRd alone and lenalidomide (R) maintenance concerning progression-free survival and other health outcomes [2]. Prof. Sonneveld presented the most recent data from the trial, focussing on MRD outcomes [1].
“Participants who had received at least 24 months of D-R maintenance therapy and reached a complete response and 12 months of sustained MRD negativity (10-5) were allowed to stop daratumumab,” mentioned Prof. Sonneveld. At the end of consolidation, MRD negativity (10-6) was achieved by 34.4% of the participants on D-VRd, whereas VRd participants reached this endpoint in 16.1% of the cases. At 36 months of follow-up, this rate increased to 63.9% in the experimental and 30.8% in the control arm, demonstrating the efficacy of D-R maintenance therapy. Furthermore, sustained MRD negativity rates (10-6; ≥12 months) were 47.3% and 18.6% in the D-VRd arm and VRd arm, respectively. For participants with high-risk disease (n=152), the corresponding sustained MRD negativity rates were 30.3% and 14.1% for experimental and control regimens. Prof. Sonneveld highlighted that 56.7% of the participants in the D-VRd arm who were MRD positive at the end of consolidation converted to MRD negativity (10-6) during D-R maintenance. This percentage was only 25.2% in the control arm.
“These data further highlight the benefit of D-VRd and D-R maintenance as a new standard of care for transplant-eligible patients with newly diagnosed MM,” concluded Prof. Sonneveld.
- Sonneveld P, et al. Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the Perseus trial. S201, EHA congress 2024, 13–16 June, Madrid, Spain.
- Sonneveld P, et al. N Engl J Med. 2024;390(4):301–313.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Post-intensification data confirm superiority of quadruple therapy in MM Next Article
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial »
« Post-intensification data confirm superiority of quadruple therapy in MM Next Article
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial »
Table of Contents: EHA 2024
Featured articles
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Post-intensification data confirm superiority of quadruple therapy in MM
Promising phase 1 results for novel CAR T-cell therapy in MM
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Can WGTS replace standard-of-care diagnostics in AML?
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Avatrombopag successful in children with chronic ITP
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
High survival rates following atezolizumab consolidation in DLBCL
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups
Related Articles
October 20, 2021
Some young people who undergo HCT retain ability to conceive
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com